Kadcyla (trastuzumab emtansine, ɑ-HER2, -EGFR, -CD340) and Adcetris (brentuximab vedotin, ɑ-CD30) are examples of antibody-drug conjugates (ADC) approved to treat recurrent breast cancer or some hematological malignancies, respectively. Here, ERBB2 is linked to breast carcinoma.